Creative Medical Technology Holdings (NASDAQ: CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem™ For Addressing Chronic Lower Back Pain - Creative Medical Tech (NASDAQ:CELZ)

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company has received clearance from the FDA to conduct a phase 1/2 clinical trial using their innovative StemSpine® treatment known as AlloStem™.

Related Keywords

United States ,Americans ,Courtney Bartlett ,Timothy Warbington ,Creative Medical Technology Holdings Inc ,National Institutes Of Health ,Clinical Development ,Creative Medical Technology ,Creative Medical Technology Holdings ,National Institutes ,Creative Medical ,Otto Norin ,